LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom’s new sensor is being developed to last 15 days—longer than the 10-day life span of its recently launched G7 CGM, pictured here. The new sensor will also be equipped with a different software ...
New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results